| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Citius Pharmaceuticals, Inc.$0.58
+0.03 (+5.74%)
F 9Pipeline Score Richly Valued Biotech · Clinical
Market Cap
19.25 M
EPS
-2.57
P/E Ratio
-
Value Trade
178.35 K
SEC Financials
Q1 2026Dilution Risk
Revenue
1.67 M
R&D Expenses
1.63 M
Total Assets
132.54 M
Total Liabilities
63.46 M
Equity
61.54 M
D/E Ratio
12,345
-3.96 %
Week
-17.52 %
1 Month
-1.25 %
3 Month
-33.23 %
6 Month
-98.74 %
5 Year
-99.81 %
All Time
Cash Data
Cash Position
4.59 M
Monthly Burn
10.73 M
Runway
0 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
72.03 K
52 Week Range
0.48 - 2.48
% held by Insiders
1.8 %
% held by Institutions
3.63 %
Enterprise Value
23.01 M
Total Shares
27.44 M
Short %
18.29 %
Float Shares
26.04 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Citius Pharmaceuticals, Inc.
387Total events
1Upcoming
118Tier-1 (high impact)
2016 – 2026Coverage
Upcoming catalysts 1
Event history 386
May 30, 2026
◆Poster PresentationLYMPHIRApprovedPresentation
Phase 1 data of LYMPHIR + pembrolizumab presented at ASCO 2026
recurrent or refractory gynecologic malignanciessource ↗
May 15, 2026
●Quarterly UpdateCorporate
Citius Pharma reports fiscal Q2 2026 financial results and business update
May 15, 2026
May 15, 2026
▲Debt Royalty FinancingCorporate
Citius Oncology secured up to $36.5 million in debt and equity financing
May 15, 2026
▲Topline ReadoutLYMPHIRApprovedClinical Data
Positive preliminary topline Phase 1 data from two investigator-initiated combination studies with LYMPHIR
CTCL (combination with pembrolizumab and prior to CAR-T)source ↗
May 15, 2026
◆FDA Feedback ReceivedMino-LokApprovedFDA Meeting
Citius Pharma actively engaged with FDA to outline next steps for Mino-Lok
catheter-related bloodstream infectionssource ↗
May 15, 2026
◆FDA Feedback ReceivedCITI-002FDA Meeting
Citius Pharma actively engaged with FDA to outline next steps for Halo-Lido
hemorrhoidssource ↗
Apr 29, 2026
▲Product LaunchLYMPHIRApprovedPost-Market
Initial shipment of LYMPHIR to Europe through regional distribution partner
relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL)source ↗
Apr 24, 2026
Mar 10, 2026
▲Topline ReadoutLYMPHIRApprovedClinical Data
Positive topline results from Phase 1 study of LYMPHIR in combination with pembrolizumab
relapsed or refractory gynecologic cancerssource ↗
Mar 4, 2026
▲Topline ReadoutLYMPHIRApprovedClinical Data
Preliminary topline Phase 1 data of LYMPHIR prior to CAR-T therapy in DLBCL
high-risk relapsed or refractory diffuse large B-cell lymphomasource ↗
Mar 4, 2026
●Oral PresentationLYMPHIRApprovedPresentation
Full results presented at 2026 ASTCT & CIBMTR Tandem Meetings
high-risk relapsed or refractory diffuse large B-cell lymphomasource ↗
Drug Pipeline Intelligence
F9
Pipeline Score $0M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 7%
Micro Cap (rank 848 of 911)
Percentile RankCitius Pharmaceuticals, Inc. has significant pipeline risk (9/100), with $97M risk-adjusted pipeline value, led by Monad 1 in Hemorrhoids (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Monad 1 Small molecule | Hemorrhoids | Phase 2 | NCT05348200 | 14% | $97M | COMPLETED | 304 | - | - | May 17, 2023 | - | Aug 31, 2023 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
LYMPHIR (denileukin diftitox-cxdl) | recurrent or refractory gynecologic malignancies | Phase 1 | 2026-05-30 | median progression free survival: 20.5 months; clinical benefit: 48% of efficacy-evaluable patients achieving clinical benefit (10 of 21); objective response rate: 33% in patients with relapsed or refractory endometrial cancer Read More | Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies Investigator-initiate Read More | |
LYMPHIR (denileukin diftitox-cxdl) | recurrent or refractory gynecologic malignancies | Phase 1 | 2026-05-30 | median progression free survival: 20.5 months; clinical benefit: 48% of efficacy-evaluable patients achieving clinical benefit (10 of 21); objective response rate: 33% in patients with relapsed or refractory endometrial cancer Read More | Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies Investigator-initiate Read More | |
LYMPHIR (denileukin diftitox-cxdl) | recurrent or refractory gynecologic malignancies | Phase 1 | 2026-05-30 | median progression free survival: 20.5 months; clinical benefit: 48% of efficacy-evaluable patients achieving clinical benefit (10 of 21); objective response rate: 33% in patients with relapsed or refractory endometrial cancer Read More | Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies Investigator-initiate Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CTXR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CTXR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CTXRCitius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies Investigator-initiate
Citius Oncology has highlighted promising Phase 1 data from an investigator-initiated study of LYMPHIR (denileukin diftitox-cxdl) combined with pembrolizumab for patients with recurrent or refractory gynecologic malignancies. The study, presented at the American Society of Clinical Oncology Annual Meeting, reported a 20.5-month median progression-free survival and notable responses in heavily pre-treated patients. While the safety profile was manageable, LYMPHIR is not approved for this indication, and its effects are still being evaluated. The company plans further clinical studies to expand understanding of this combination therapy in gynecologic cancers.
Read more →CTXRCitius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals reported strong financial results for the fiscal second quarter of 2026, with $5.6 million in net revenue from the launch of LYMPHIR. The company secured near 100% payer coverage and reported positive topline results from Phase 1 studies. However, it also faced a net loss of $21.2 million, primarily due to increased administrative expenses.
Read more →CTXRCitius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update $5.6 Million in net revenue for the first half of fiscal 2026 from ongoing launch of LYMPHIR Citius Pharma ra
Citius Pharmaceuticals, Inc. reported financial results for the fiscal second quarter of 2026, highlighting $5.6 million in net revenue from the commercial launch of LYMPHIR. The company noted that 83% of target accounts have either been included on formularies or are under review, with payer coverage reaching near 100% for commercial lives. Additionally, Citius Oncology secured $36.5 million in financing to support its commercial activities, while positive Phase 1 data further bolstered the potential of LYMPHIR in combination treatments. The report reflects significant strides in establishing a sustainable market presence.
Read more →CTXR▼ -8.5%on this news
Citius Oncology Ships First International Order of LYMPHIR to Europe Order fulfilment expands international patient access to LYMPHIR following initial U.S. launch Distribution by regional partners through Named Patient
Citius Oncology has successfully shipped LYMPHIR (denileukin diftitox-cxdl) to Europe, marking a significant milestone in expanding treatment access for patients with cutaneous T-cell lymphoma. The therapy will be made available through Named Patient Programs, adhering to local regulations. This international order follows the treatment's initial U.S. launch and demonstrates the company's commitment to providing options in markets where alternatives are limited. LYMPHIR is approved for patients with Stage I-III relapsed or refractory disease after prior systemic therapy.
Read more →CTXR▼ -17.5%on this news· ran to -36% by day 3shared move
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals has announced the closing of a registered direct offering, raising approximately $5 million. The funds will be utilized to support the commercial launch of its product LYMPHIR, along with other development initiatives. The offering included the sale of common stock and unregistered warrants, with H.C. Wainwright & Co. acting as the placement agent.
Read more →CTXR▼ -17.5%on this news· ran to -36% by day 3shared move
Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At- The-Market Under Nasdaq Rules Cranford, NJ
Citius Pharmaceuticals Inc. has announced a registered direct offering of approximately $5 million through the purchase of over 5 million shares of its common stock. This offering is priced at-the-market under Nasdaq rules and is part of a broader strategy to support the commercial launch of LYMPHIR and further development of other pipeline candidates. The transaction is subject to customary closing conditions and is expected to close on approximately April 24, 2026.
Read more →CTXR▲ +32.3%on this news
Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting Early Adoption and Expanding Clinical Development Broad institutional uptake among leading cancer centers and payer coverage supports early prescr
Citius Oncology has provided a commercial update on the U.S. launch of LYMPHIR, an FDA-approved treatment for cutaneous T-cell lymphoma. The update highlights significant early adoption among oncology centers and expanding payer coverage, which support the therapy's uptake. The company is also advancing clinical development through collaborations with prominent academic institutions to explore LYMPHIR's potential in broader oncology applications. Initial market projections indicate that the demand for LYMPHIR is substantial, with ongoing efforts to establish a strong commercial presence and educational outreach to care providers.
Read more →CTXR▲ +11%on this news
Citius Oncology Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of LYMPHIR in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers Study data from patients with relaps
Citius Oncology announced positive topline results from an investigator-initiated Phase 1 study of LYMPHIR combined with pembrolizumab for patients with relapsed or refractory gynecologic cancers. Conducted by the University of Pittsburgh, the study revealed a 24% objective response rate and a favorable safety profile. The findings indicate potential augmented efficacy of the combined therapy, warranting further investigation in Phase 2 trials. Results will be presented at an upcoming international cancer conference.
Read more →CTXR▲ +10.3%on this news· ran to +28% by day 1
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR (E7777) Dosing Prior to Commercial CAR-T Therapy in High-Risk Diffuse Large B-Cell Lymphoma Topline data of investigator-initiated study at
Citius Oncology has announced positive preliminary results from a Phase 1 trial of LYMPHIR (E7777) in patients with high-risk diffuse large B-cell lymphoma (DLBCL), demonstrating an 86% overall response rate. The trial showed no dose-limiting toxicities, indicating a favorable safety profile. These encouraging findings suggest that LYMPHIR could enhance the effectiveness of existing CAR-T therapies, particularly in patients exhibiting poor prognostic features. The first results were presented at the 2026 ASTCT & CIBMTR Tandem Meetings.
Read more →CTXR▲ +12.7%on this news
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals has secured $3.8 million in non-dilutive capital through New Jersey's NOL Program. This funding will support the commercial launch of LYMPHIR and advance its late-stage pipeline programs. The CFO emphasized the importance of this capital for enhancing the company's financial flexibility and long-term shareholder value.
Read more →CTXRCitius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter
Citius Pharmaceuticals, Inc. announced its first reported revenue following the successful launch of LYMPHIR, generating $3.9 million in sales during the fiscal first quarter ending December 31, 2025. The company, which focuses on critical care products, expressed optimism about future growth opportunities, including expanding access to their therapies. CEO Leonard Mazur highlighted the significance of LYMPHIR as a new treatment option for patients with relapsed or refractory cutaneous T-cell lymphoma. Additionally, the company is committed to advancing its late-stage pipeline.
Read more →CTXRCitius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals announced its first reported revenue of $3.9 million following the launch of LYMPHIR for cutaneous T-cell lymphoma. The company is optimistic about future growth, citing early physician adoption and international access initiatives. However, it also reported a net loss of $8.2 million, indicating ongoing financial challenges. The company remains focused on advancing its late-stage pipeline.
Read more →CTXR▼ -23%on this news
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
Citius Pharmaceuticals reported its fiscal year 2025 results, highlighting the successful launch of LYMPHIR, an FDA-approved immunotherapy for CTCL patients. The company aims to drive adoption of LYMPHIR in 2026 while exploring further indications and markets. Citius is also focused on strengthening its financial foundation and advancing its late-stage pipeline products.
Read more →CTXRCitius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals, Inc. reported its fiscal year 2025 financial results, highlighting the successful launch of LYMPHIR, an FDA-approved immunotherapy for cutaneous T-cell lymphoma. The company raised approximately $61 million in capital and is focused on driving LYMPHIR's adoption while engaging with the FDA on future products. Despite a net loss of $39.7 million, the company sees significant market potential for LYMPHIR.
Read more →CTXR▼ -6.2%on this news
NASDAQ: CTXR Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) Corporate Overview DECEMBER 2025 FORWARD - LOOKING STATEMENTS NASDAQ: CTXR 2 This presentation has been prepared by Citius Pharmaceuticals, Inc . (the "Company") f
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) recently provided a corporate overview highlighting its strategic initiatives and future plans. The company has launched LYMPHIR, a new treatment for relapsed or refractory Stage I-III cutaneous T-cell lymphoma, enhancing its oncology portfolio. Additionally, they reported positive results from the Mino-Lok Phase 3 trial. However, they acknowledge substantial funding needs and potential risks in commercialization and operational execution.
Read more →CTXR▲ +9.6%on this news
This presentation has been prepared by Citius Pharmaceuticals, Inc . (the "Company") for informational purposes only and not for any other purpose . Nothing contained in this presentation is, or should be construed as, a
Citius Pharmaceuticals, Inc. has presented an overview outlining its plans for commercializing LYMPHIR, a treatment for cutaneous T-cell lymphoma (CTCL), which received FDA approval in August 2024. The company has invested over $90 million to prepare for the anticipated launch in Q4 2025, focusing on various pre-commercial activities including inventory manufacturing and supply chain agreements. Citius also highlights its strategic partnerships and the expected market demand, forecasting significant opportunities in the treatment of CTCL.
Read more →CTXR▼ -7.2%on this newsshared move
Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules Cranford, NJ
Citius Pharmaceuticals has announced a registered direct offering priced at-the-market, aiming to raise $6 million by selling nearly 4 million shares of its common stock and associated warrants. The proceeds from this offering are intended to support the commercial launch of LYMPHIR and fund development initiatives for other products. The offering is contingent upon customary closing conditions, and while investor interest appears strong, the company also indicates risks related to funding and operational execution.
Read more →CTXR▼ -7.2%on this newsshared move
Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals announced the closing of a registered direct offering, raising approximately $6.0 million. The offering included 3,973,510 shares priced at $1.51 each, with accompanying common warrants. The proceeds will be used to support the launch of LYMPHIR™, alongside other development initiatives. H.C. Wainwright & Co. acted as the exclusive placement agent.
Read more →CTXRCitius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) and Citius Oncology, Inc. (Nasdaq: CTOR) today announced that management will be participating in three...
Citius Pharmaceuticals and Citius Oncology will participate in three investor conferences in October 2025. The events include the LD Micro Main Event XIX, the 2025 Maxim Growth Summit, and the Think Equity Conference. These conferences will provide opportunities for one-on-one meetings with management and showcase the companies' advancements, including the recent FDA approval of LYMPHIR.
Read more →CTXRCitius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development...
Citius Pharmaceuticals reported its fiscal third quarter 2025 results, highlighting a successful fundraising of $12.5 million and an additional $9 million raised by its oncology subsidiary. The company is preparing for the U.S. launch of LYMPHIR, an immunotherapy for cutaneous T-cell lymphoma, while also focusing on its other product candidates. Despite a net loss of $9.2 million for the quarter, Citius is positioned for growth as it transitions to a commercial organization.
Read more →CTXRCitius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update $12.5 million in gross financings raised during the quarter, with an additional $9 million raised by Citius On
Citius Pharmaceuticals, Inc. announced its financial results for the fiscal third quarter of 2025, highlighting a successful fundraising period with $12.5 million raised alongside an additional $9 million by its oncology subsidiary. The company is gearing up for the U.S. launch of LYMPHIR targeted at cutaneous T-cell lymphoma, reflecting its transition towards commercial operations. Significant preparatory work for market introduction is ongoing, with finalizing manufacturing and distribution agreements. The company also remains focused on the development of Mino-Lok, engaging with the FDA to outline future steps.
Read more →CTXR▼ -8.1%on this news· ran to -26% by day 3
Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement CRANFORD, N.J.
Citius Pharmaceuticals announced its compliance with Nasdaq's minimum bid price requirement after its stock closed at $1.00 per share for ten consecutive trading days. The company expressed satisfaction with this achievement, emphasizing its commitment to bringing critical care products to market. As a result, the previously scheduled Nasdaq Hearing Panel has been canceled, allowing Citius Pharma to continue its stock listing on Nasdaq. The company's product pipeline includes FDA-approved therapies and ongoing clinical trials.
Read more →CTXR▼ -8.1%on this news· ran to -26% by day 3
Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) today announced that it has received formal notification from The...
Citius Pharmaceuticals has announced that it has regained compliance with Nasdaq's minimum bid price requirement after its stock closed at $1.00 or greater for 10 consecutive trading days. This compliance allows the company's securities to remain listed on the Nasdaq Stock Market. CEO Leonard Mazur expressed satisfaction with this achievement, highlighting the company's commitment to developing critical care products.
Read more →CTXR▼ -8.9%on this news
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals has completed a registered direct offering, raising approximately $6 million upfront, with potential additional proceeds of $9.8 million from short-term warrants. The funds will support the commercial launch of LYMPHIR, a targeted immunotherapy approved by the FDA. The offering was facilitated by H.C. Wainwright & Co. and follows a shelf registration statement.
Read more →CTXR▼ -22.6%on this news· ran to -36% by day 3shared move
Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules $6 million upfront with up to an additional $9.8 million of potential aggregate gross proceeds
Citius Pharmaceuticals has announced a registered direct offering aiming to raise up to $15.8 million, consisting of $6 million upfront and an additional potential $9.8 million through short-term warrants. The offering will involve 4,920,000 shares priced at $1.22 each, and the closing is expected on June 11, 2025. The proceeds will be used for the commercial launch of LYMPHIR and other corporate purposes. The company holds a strong pipeline of critical care products, including ongoing FDA engagements for its other therapies.
Read more →CTXR▼ -22.6%on this news· ran to -36% by day 3shared move
Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals has announced a registered direct offering to raise up to $15.8 million, with an initial $6 million expected from the sale of shares and potential additional proceeds from short-term warrants. The funds will primarily support the commercial launch of LYMPHIR™, an FDA-approved immunotherapy. The offering is set to close around June 11, 2025, pending customary conditions.
Read more →CTXR▲ +61%on this newsshared move
Citius Oncology Enters into Distribution Services Agreement with Cardinal Health Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq:...
Citius Oncology has entered a distribution services agreement with Cardinal Health to facilitate the launch of LYMPHIR, an FDA-approved immunotherapy for cutaneous T-cell lymphoma. This partnership aims to ensure efficient access to the treatment for healthcare providers and patients. LYMPHIR has shown promise in depleting immunosuppressive T lymphocytes and has a significant market potential.
Read more →CTXR▲ +19.2%on this news
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update CRANFORD, N.J.
Citius Pharmaceuticals, Inc. announced their fiscal second quarter 2025 financial results, highlighting a net loss of $11.5 million. Despite the losses, the company is focused on launching its FDA-approved product LYMPHIR and preparing a New Drug Application for the Mino-Lok program, which has demonstrated successful clinical outcomes. The company successfully raised $6 million through equity offerings to support its financial position but will need further funding to continue operations beyond May 2025.
Read more →CTXR▲ +19.2%on this news
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals reported its fiscal second quarter 2025 financial results, highlighting the upcoming launch of its FDA-approved product, LYMPHIR. The company is actively seeking financing and exploring partnerships to support its strategy. Despite a net loss of $11.5 million, Citius Pharma remains focused on advancing its pipeline, including the Mino-Lok program, which successfully completed its Phase 3 trial.
Read more →CTXR▲ +5.3%on this news
Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) and its oncology subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR), today announced that Leonard Mazur,...
Citius Pharmaceuticals, Inc. will have CEO Leonard Mazur present at the Jefferies Global Healthcare Conference on June 5, 2025. The conference will take place in New York City, and Mazur will also engage in one-on-one meetings with investors. Citius Oncology's FDA-approved therapy, LYMPHIR, is positioned in a growing market for oncology treatments.
Read more →CTXR▼ -19.5%on this news· ran to -32% by day 3
Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock Cranford, NJ
Citius Pharmaceuticals has announced a definitive agreement for a registered direct offering of common stock, expected to raise $2 million. The funds will primarily support the commercial launch of LYMPHIR, a recently FDA-approved targeted immunotherapy for cutaneous T-cell lymphoma. The offering involves the purchase of approximately 1.74 million shares at $1.15 per share, facilitated by H.C. Wainwright & Co. The transaction is anticipated to close around April 2, 2025, pending customary closing conditions.
Read more →CTXR▼ -19.5%on this news· ran to -32% by day 3
Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals announced a $2 million registered direct offering of common stock, selling 1,739,131 shares at $1.15 each. The proceeds will support the launch of LYMPHIR and other corporate purposes. The offering is contingent on customary closing conditions and follows the recent FDA approval of LYMPHIR for cutaneous T-cell lymphoma.
Read more →CTXRCitius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals, Inc. reported its fiscal first quarter 2025 financial results, highlighting advancements in the commercial launch of LYMPHIR and securing a new J-code. The company also presented promising data from a Phase I trial involving LYMPHIR and pembrolizumab. However, it faced an increased net loss and rising general and administrative expenses.
Read more →CTXRCitius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update CRANFORD, N.J.
Citius Pharmaceuticals, Inc. released its fiscal first quarter 2025 financial results, showing progress in key areas including preparations for the launch of its therapy LYMPHIR. The company reported a net loss of $10.3 million, reflecting rising administrative costs but decreasing R&D expenses. Citius also highlighted ongoing discussions with potential partners and the completion of significant trials for its pipeline products. The financial position remains a focus as they seek additional funding to support operations.
Read more →CTXRCitius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius Oncology, Inc. ("Citius...
Citius Pharmaceuticals and its subsidiary Citius Oncology announced the issuance of a permanent J-code (J9161) for LYMPHIR, effective April 1, 2025. This coding will assist healthcare providers in billing and reimbursement for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL). The J-code aims to improve patient access and support the administration of LYMPHIR, which was approved by the FDA in August 2024.
Read more →CTXRCitius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services - Permanent J-Code (J9161) expected to be effective
Citius Pharmaceuticals and Citius Oncology announced that their drug LYMPHIR has received a unique permanent J-code (J9161) from the Centers for Medicare & Medicaid Services, effective April 1, 2025. This coding will streamline reimbursement for healthcare providers administering LYMPHIR, which is indicated for adults with relapsed or refractory Stage I-III cutaneous T-cell lymphoma. This milestone is expected to improve patient access to the therapy, as it outlines the billing process for providers. However, LYMPHIR comes with potential risks, including capillary leak syndrome and other significant adverse effects.
Read more →CTXR▼ -15.1%on this news
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals has announced a registered direct offering of approximately $3 million, selling 743,496 shares at $4.035 each. The proceeds will be used for general corporate purposes, including the development of its product candidates. The offering is expected to close around January 8, 2025, pending customary conditions.
Read more →CTXR▼ -15.1%on this news
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules Cranford, NJ
Citius Pharmaceuticals has announced a registered direct offering expected to raise $3 million by selling approximately 743,496 shares of its common stock at a price of $4.035 per share. The company aims to use the net proceeds for general corporate purposes, including the development of its product candidates. The offering, arranged by H.C. Wainwright & Co., is contingent upon satisfying standard closing conditions. This move follows the recent FDA approval of its immunotherapy product, LYMPHIR, indicating progress in its product pipeline.
Read more →CTXR▲ +11.8%on this newsshared move
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius Oncology (Nasdaq: CTOR),...
Citius Pharmaceuticals and its subsidiary, Citius Oncology, are preparing for the commercial launch of LYMPHIR, an immunotherapy for relapsed or refractory cutaneous T-cell lymphoma, expected in the first half of 2025. Following its FDA approval in August 2024, the company is finalizing manufacturing, marketing, and reimbursement strategies. Key initiatives include securing supply agreements and enhancing healthcare provider engagement.
Read more →CTXR▲ +11.8%on this newsshared move
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 CRANFORD, N.J.
Citius Pharmaceuticals and its subsidiary Citius Oncology are preparing for the commercial launch of LYMPHIR, an innovative immunotherapy for relapsed or refractory cutaneous T-cell lymphoma, expected in the first half of 2025. Since its FDA approval in August 2024, Citius has been finalizing manufacturing and marketing efforts for the drug. The company aims to penetrate the U.S. market effectively while exploring licensing opportunities globally. LYMPHIR has demonstrated potential antitumor activity but carries risks including capillary leak syndrome and infusion-related reactions, which require careful patient monitoring.
Read more →CTXR▲ +11.2%on this news
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals reported its fiscal year 2024 results, highlighting FDA approval for LYMPHIR, an immunotherapy for CTCL. The company is preparing for the commercial launch of LYMPHIR in 2025 and has successfully merged its oncology subsidiary. Despite progress, Citius faced a net loss of $39.4 million and decreasing cash reserves, indicating financial challenges ahead.
Read more →CTXR▲ +11.2%on this news
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J.
Citius Pharmaceuticals, Inc. reported its fiscal 2024 financial results, achieving a transformative year marked by its first FDA approval of LYMPHIR and significant clinical milestones. The company plans to launch LYMPHIR in the first half of 2025 and is focusing on regulatory strategies for its other products, Mino-Lok and Halo-Lido. However, Citius Pharma also reported an increased net loss and rising administrative expenses. The company is exploring partnerships and plans to raise additional capital to support its operations moving forward.
Read more →CTXRCitius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok Program and Pathway to Approval CRANFORD, N.J.
Citius Pharmaceuticals announced a successful Type C meeting with the FDA concerning its Phase 3 Mino-Lok program. The FDA offered constructive feedback aimed at supporting a future New Drug Application submission for Mino-Lok, which is a catheter lock solution to address serious infections. The meeting focused on trial data, safety, and regulatory considerations. Citius reaffirms its commitment to advancing Mino-Lok, emphasizing its potential impact on patient care and healthcare costs.
Read more →CTXRCitius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals announced a productive Type C meeting with the FDA regarding its Mino-Lok program, which aims to salvage central venous catheters. The FDA provided actionable guidance that supports a future New Drug Application submission. Mino-Lok has demonstrated compelling clinical outcomes in its Phase 3 trial, indicating its potential to improve patient care and reduce healthcare costs.
Read more →CTXR▼ -19%on this newsshared move
Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split CRANFORD, N.J.
Citius Pharmaceuticals, Inc. has announced a 1-for-25 reverse stock split that will take effect on November 25, 2024. This action is intended to increase the company's stock price to comply with Nasdaq's minimum bid price requirement. The reverse split will reduce the number of outstanding shares significantly, while all fractional shares will be rounded up to the nearest whole share. Notably, the Board of Directors executed this split under Nevada law, without needing shareholder approval.
Read more →CTXR▼ -19%on this newsshared move
Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) announced today that it will be executing a reverse stock split of its ...
Citius Pharmaceuticals, Inc. announced a 1-for-25 reverse stock split to increase its share price and comply with Nasdaq listing requirements. The split will take effect on November 25, 2024, and will reduce the number of outstanding shares significantly. The company aims to enhance its market position while continuing to develop its pipeline of critical care products.
Read more →CTXR▲ +12.1%on this news
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals has successfully closed a registered direct offering, raising $3 million through the sale of 12 million shares and accompanying warrants. The funds will support general corporate purposes, including pre-clinical and clinical development. The company has a promising pipeline, including FDA-approved LYMPHIR and ongoing trials for Mino-Lok and Halo-Lido.
Read more →CTXR▼ -39.1%on this newsshared move
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals has announced a registered direct offering of 12 million shares at $0.25 each, aiming to raise $3 million. The proceeds will support general corporate purposes, including clinical development. The offering is set to close around November 18, 2024, pending customary conditions. The company is also navigating various operational risks.
Read more →CTXR▼ -39.1%on this newsshared move
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Cranford, NJ
Citius Pharmaceuticals has announced a registered direct offering that will raise $3 million through the sale of 12 million shares of its common stock along with warrants. The offering is set to close on or about November 18, 2024, and the funds raised are intended for general corporate purposes, including development activities. Citius Pharma's recent FDA approval for its immunotherapy product and successful completion of pivotal trials highlights its ongoing commitment to expanding its product pipeline.
Read more →CTXR▲ +9.2%on this news· ran to -20% by day 3
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA ) and LYMPHIR in Cancer Patients with Recurrent
Citius Pharmaceuticals and Citius Oncology have reported encouraging preliminary results from an ongoing Phase I clinical trial assessing a combination of pembrolizumab and LYMPHIR in patients with recurrent solid tumors, particularly gynecological cancers. The study has shown a 27% objective response rate and a 33% clinical benefit rate with a median progression-free survival of 57 weeks. The regimen was well tolerated, with no significant immune-related adverse events, indicating its potential effectiveness. The trial continues to enroll additional patients to deepen the understanding of the treatment's impact on the tumor microenvironment.
Read more →CTXR▲ +9.2%on this news· ran to -20% by day 3
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), today...
Citius Pharmaceuticals and Citius Oncology announced promising preliminary results from a Phase I clinical trial of pembrolizumab and LYMPHIR in patients with recurrent solid tumors, particularly gynecological cancers. The trial reported a 27% objective response rate and a median progression-free survival of 57 weeks. The regimen was well-tolerated, with no serious immune-related adverse events documented. Further research is planned to explore the therapy's impact on various solid tumor types.
Read more →CTXRCitius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology CRANFORD, N.J.
Citius Pharmaceuticals announced that its immunotherapy LYMPHIR has been included in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Cutaneous T-cell Lymphoma (CTCL). This recommendation signifies a consensus that the treatment is appropriate for patients who have experienced relapse or refractory CTCL following previous systemic therapies. LYMPHIR's recent FDA approval, based on successful Phase 3 clinical trials, highlights its potential in improving patient outcomes. The NCCN guidelines are known for influencing clinical practices and reimbursement decisions in oncology.
Read more →CTXRCitius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), today announced that Chairman and CEO Leonard Mazur will present and...
Citius Pharmaceuticals announced that CEO Leonard Mazur will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024. The presentation will cover recent developments, including the FDA approval of LYMPHIR for cutaneous T-cell lymphoma and the merger forming Citius Oncology. The company also achieved significant milestones in its Phase 3 trial for Mino-Lok.
Read more →CTXRCitius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), today...
Citius Pharmaceuticals and Citius Oncology announced that LYMPHIR has been included in the NCCN Clinical Practice Guidelines for Oncology. This immunotherapy, recently approved by the FDA, is indicated for patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). The NCCN's endorsement is expected to enhance treatment accessibility and support clinical decision-making for healthcare professionals.
Read more →CTXR▼ -11.7%on this news
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. LYMPHIR for the treatment of cutaneous T-cell lymphoma approved by the FDA Citius Pharmaceuticals, Inc. holds approximat
Citius Pharmaceuticals has completed the merger of its subsidiary with TenX Keane Acquisition, establishing Citius Oncology, Inc., which focuses on the development of targeted oncology therapies. The newly formed entity, set to trade under the ticker CTOR, aims to advance its primary asset, LYMPHIR, recently approved by the FDA for adult patients with relapsed or refractory cutaneous T-cell lymphoma. This merger is expected to provide financial flexibility and unlock additional growth opportunities in the oncology market.
Read more →CTXR▼ -11.7%on this news
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update Granted FDA approval of LYMPHIR in treatment of cutaneous T-cell lymphoma Completed merger of oncology subsidi
Citius Pharmaceuticals, Inc. reported its fiscal Q3 2024 results, highlighting the FDA's approval of LYMPHIR for cutaneous T-cell lymphoma, marking a significant achievement for the company. The merger of its oncology subsidiary with TenX Keane is set to enhance Citius Oncology's operations, which will begin trading on Nasdaq under CTOR. While the financial report showed an increase in net loss and R&D expenses, the company has secured additional funding and met significant milestones in its development pipeline, particularly for Mino-Lok.
Read more →CTXR▼ -11.4%on this news· ran to -25% by day 3shared move
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development...
Citius Pharmaceuticals reported significant business developments in its fiscal third quarter of 2024, including FDA approval for LYMPHIR, an immunotherapy for cutaneous T-cell lymphoma. The company also completed a merger with TenX Keane, forming Citius Oncology, and achieved key milestones in its Mino-Lok Phase 3 trial. Despite these advancements, the company reported a net loss of $10.6 million, reflecting ongoing financial challenges.
Read more →CTXR▼ -11.4%on this news· ran to -25% by day 3shared move
Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development...
Citius Pharmaceuticals has completed a merger with TenX Keane to form Citius Oncology, which will begin trading under the ticker CTOR on August 13, 2024. This merger aims to enhance financial flexibility and focus on the commercialization of LYMPHIR, recently approved by the FDA for cutaneous T-cell lymphoma. Citius Pharma retains a 90% stake in the new entity, allowing for potential growth in oncology therapies.
Read more →CTXR▼ -11.4%on this news· ran to -25% by day 3shared move
Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), today announced that it will host an investor call on Tuesday, August ...
Citius Pharmaceuticals will host an investor call on August 13, 2024, to discuss recent and upcoming developments. The call will feature CEO Leonard Mazur and the management team, followed by a Q&A session. The company recently received FDA approval for LYMPHIR, an immunotherapy for cutaneous T-cell lymphoma, and has completed pivotal trials for its other products.
Read more →CTXRCitius Pharmaceuticals Receives FDA Approval for LYMPHIR (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma Only systemic treatment for relapsed or
Citius Pharmaceuticals announced that LYMPHIR (denileukin diftitox-cxdl) has received FDA approval for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL). This approval signifies the first indication for LYMPHIR and marks a milestone as the only FDA-approved treatment of its kind targeting IL-2 receptors on malignant T-cells. With a rapid median time-to-response and the potential to significantly improve patients' quality of life, LYMPHIR may change the treatment landscape for CTCL. However, its safety profile includes adverse reactions and requires careful monitoring.
Read more →CTXRCitius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) ("Citius", "Citius Pharma"), announced today that the U.S. Food and Drug Administration (FDA) has...
Citius Pharmaceuticals has received FDA approval for LYMPHIR™ (denileukin diftitox-cxdl), a new immunotherapy for adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL). This marks the first novel systemic treatment for CTCL since 2018, based on Phase 3 study results demonstrating a 36% objective response rate. LYMPHIR is expected to launch within five months, offering hope for patients with limited treatment options.
Read more →CTXRCitius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc. Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development...
Citius Pharmaceuticals announced that shareholders of TenX Keane approved the merger with its oncology subsidiary, which will be renamed Citius Oncology. The merger is expected to enhance access to public equity markets and support the commercialization of LYMPHIR, pending FDA approval. Citius Pharma will retain a 90% stake in the new entity, positioning it for future oncology developments.
Read more →CTXR▲ +10.3%on this news
Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates Multiple catalysts for potentially transformative assets in second half of 2024 Strong momentum expected from positive topline results of Phase 3...
Citius Pharmaceuticals has outlined significant near-term milestones for its late-stage candidates, Mino-Lok and LYMPHIR, with expected catalysts in the second half of 2024. Positive topline results from the Phase 3 Mino-Lok trial suggest its potential as a standard treatment for catheter-related bloodstream infections. The FDA is reviewing the Biologics License Application for LYMPHIR, with a decision anticipated on August 13, 2024. The company is also preparing for commercialization efforts if LYMPHIR is approved.
Read more →CTXRCitius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals will host an investor call on June 3, 2024, to discuss the topline results of its Phase 3 Trial for Mino-Lok, an antibiotic lock solution. CEO Leonard Mazur and the management team will address the clinical need for Mino-Lok in treating catheter-related bloodstream infections. A Q&A session will follow their presentation.
Read more →CTXR▲ +10.6%on this news
Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution Trial achieves statistically significant primary endpoint (p=0.0006) Secondary endpoint demonstrates s
Citius Pharmaceuticals has announced positive topline results from its Phase 3 trial of Mino-Lok, a novel antibiotic lock solution for patients with catheter-related bloodstream infections. The study met its primary endpoint, showing statistically significant improvement in catheter retention. With a notable percentage of patients achieving overall treatment success, Citius aims to engage with the FDA to advance Mino-Lok towards potential approval. This new solution offers an alternative to traditional catheter removal, promising enhanced patient care.
Read more →CTXR▲ +10.6%on this news
Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals announced positive topline results from its Phase 3 trial of Mino-Lok, an antibiotic lock solution for catheter-related infections. The trial met its primary endpoint with a significant improvement in catheter retention time compared to control. Secondary outcomes also showed a higher success rate for Mino-Lok therapy. The company plans to engage with the FDA for further development.
Read more →CTXRCitius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals reported its fiscal second quarter 2024 results, highlighting significant progress in its pipeline. The FDA accepted the biologics license application for LYMPHIR, with a target action date of August 13, 2024. Additionally, topline results for the Mino-Lok Phase 3 trial are expected soon. However, the company recorded an increased net loss compared to the previous year.
Read more →CTXRCitius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update Mino-Lok data analysis on track with topline results anticipated this quarter LYMPHIR biologics license appli
Citius Pharmaceuticals, Inc. reported fiscal Q2 2024 financial results, highlighting progress with its product pipeline. The data analysis for Mino-Lok is on track, with topline results expected soon. The FDA has accepted the biologics license application for LYMPHIR, which has a target action date of August 13, 2024. Despite a challenging capital market, the company completed a $15 million capital raising to support its operations.
Read more →CTXRCitius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals will participate in the EF Hutton Annual Global Conference and the H.C. Wainwright BioConnect Investor Conference. CEO Leonard Mazur will host one-on-one meetings at both events, showcasing the company's commitment to investor relations. The company is focused on developing critical care products and has ongoing trials and FDA reviews for its product candidates.
Read more →CTXR▲ +7.8%on this news
Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals has successfully closed a registered direct offering, raising approximately $15 million by selling 21,428,574 shares of common stock at $0.70 each. The proceeds will be utilized for general corporate purposes, including the development of its product candidates. Notably, the company is advancing its late-stage immunotherapy LYMPHIR for cutaneous T-cell lymphoma, which is currently under FDA review.
Read more →CTXR▼ -9.3%on this newsshared move
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals has announced a registered direct offering to raise approximately $15 million by selling 21,428,574 shares at $0.70 each, along with warrants. The funds will be allocated for general corporate purposes, including the development of its product candidates. The offering is expected to close around April 30, 2024, pending customary conditions.
Read more →CTXR▼ -9.3%on this newsshared move
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering Cranford, NJ
Citius Pharmaceuticals has announced a registered direct offering of 21,428,574 shares of its common stock and warrants, aiming to raise around $15 million. The offering is set to close around April 30, 2024, subject to customary conditions. The net proceeds will be used for general corporate purposes, including the development of its product candidates. Citius is notably developing LYMPHIR, an immunotherapy for cutaneous T-cell lymphoma, with its FDA review targeting August 2024.
Read more →CTXRCitius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing...
Citius Pharmaceuticals announced the addition of City of Hope to the University of Minnesota's Phase 1 trial of LYMPHIR in combination with CAR-T therapy for B-cell lymphoma. This expansion aims to evaluate the maximum tolerated dose of LYMPHIR alongside CAR-T treatments. The trial is led by distinguished oncologists and seeks to enhance anti-tumor activity through innovative immunotherapy approaches.
Read more →CTXRCitius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals announced that its Chairman and CEO, Leonard Mazur, will present at the LD Micro Invitational XIV investor conference on April 9, 2024. The company is focused on developing critical care products and has a diversified pipeline, including late-stage candidates like Mino-Lok and LYMPHIR. The latter is under FDA review with a PDUFA date set for August 2024.
Read more →CTXRCitius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals announced that the FDA has accepted its Biologics License Application (BLA) resubmission for LYMPHIR (denileukin diftitox) aimed at treating relapsed or refractory cutaneous T-cell lymphoma (CTCL). The FDA set a PDUFA target action date of August 13, 2024. The acceptance reflects a complete response to previous FDA feedback, with no safety or efficacy concerns noted.
Read more →CTXRCitius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma FDA assigns Prescription Drug Use
Citius Pharmaceuticals announced the FDA's acceptance of its resubmission of the Biologics License Application (BLA) for LYMPHIR, an immunotherapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL). The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of August 13, 2024. This follows a Complete Response Letter received in July 2023, and Citius states that safety and efficacy issues were not mentioned in the FDA's latest communication. The approval would provide an important treatment option for patients suffering from this condition.
Read more →CTXRCitius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals has announced the receipt of $2.4 million in non-dilutive capital through New Jersey's Technology Business Tax Certificate Transfer Program. This funding will allow the company to convert certain operational losses into cash, aiding in the advancement of its critical care product pipeline. The NJEDA's support enhances Citius's financial flexibility as it prepares for upcoming clinical trials.
Read more →CTXRCitius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals has filed a Form S-3 shelf registration statement to replace its expiring registration. This move is part of the company's ongoing efforts to support its late-stage product candidates, including Mino-Lok and LYMPHIR. The company is also advancing its Phase 2b trial for CITI-002, indicating a strong pipeline.
Read more →CTXRCitius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals announced its participation in the BIO CEO and Investor Conference and the Sidoti Small-Cap Virtual Conference. CEO Leonard Mazur will present at both events, highlighting the company's progress in developing critical care products. Citius has completed enrollment in a Phase 3 trial for Mino-Lok and a Phase 2b trial for CITI-002.
Read more →CTXR▲ +13.5%on this news· ran to +24% by day 1
Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals has resubmitted its Biologics License Application for LYMPHIR™ (denileukin diftitox) to the FDA for treating relapsed or refractory cutaneous T-cell lymphoma. This resubmission follows a Complete Response Letter received in July 2023, which the company believes it has adequately addressed. The FDA is expected to accept the resubmission and issue a PDUFA date within 30 days.
Read more →CTXR▲ +13.5%on this news· ran to +24% by day 1
Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma FDA acceptance of the completed resubm
Citius Pharmaceuticals announced the resubmission of its Biologics License Application (BLA) for LYMPHIR, an immunotherapy for relapsed or refractory cutaneous T-cell lymphoma, to the FDA. This resubmission follows a Complete Response Letter from July 2023, which the company addressed by enhancing product testing and manufacturing controls. The FDA is expected to release a Prescription Drug User Fee Act (PDUFA) date within 30 days. LYMPHIR has previously received orphan drug designation, demonstrating its significance in treating this type of lymphoma.
Read more →CTXR▲ +13.5%on this news· ran to +24% by day 1
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update Resubmitted LYMPHIR Biologics License Application; awaiting PDUFA date Completed enrollment in the Mino-Lok Pi
Citius Pharmaceuticals, Inc. reported its fiscal first quarter 2024 results, highlighting significant milestones such as the completion of enrollment in the Mino-Lok Phase 3 trial and the resubmission of the LYMPHIR Biologics License Application addressing previous FDA concerns. Financially, the company has $20.3 million in cash, which is projected to sustain operations through August 2024, although it anticipates future capital needs. Additionally, the planned merger with TenX aims to enhance financial stability and stakeholder value. The company is awaiting a PDUFA date for LYMPHIR and expects topline results from the Mino-Lok trial in the second quarter of 2024.
Read more →CTXR▲ +13.5%on this news· ran to +24% by day 1
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals reported its fiscal first quarter 2024 results, highlighting the resubmission of the LYMPHIR biologics license application and completion of the Mino-Lok Phase 3 trial enrollment. The company anticipates topline results in Q2 2024 and has scheduled an FDA meeting for Halo-Lido. Financially, Citius reported a net loss of $9.2 million, with increased operational costs and a need for future capital.
Read more →CTXRCitius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals has nominated Robert J. Smith, a seasoned pharmaceutical executive, to its Board of Directors, pending shareholder approval at the Annual Meeting in March 2024. Smith's extensive experience includes leadership roles at Pfizer and Wyeth, focusing on business growth and strategy. His addition is seen as pivotal for Citius as it transitions to a commercial organization.
Read more →CTXRCitius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors Independent Director nominee expected to be elected at Annual Shareholders' Meeting in March 2024 CRANFORD
Citius Pharmaceuticals has nominated Robert J. Smith, a seasoned pharmaceutical executive, to its Board of Directors, pending shareholder approval at the upcoming Annual Shareholders' Meeting in March 2024. With over three decades of experience at major companies like Pfizer and Wyeth, Smith brings valuable insights for Citius as it evolves into a commercial enterprise. This strategic addition aims to bolster the company's growth and enhance its focus on patient care and shareholder interests.
Read more →CTXR▲ +6.9%on this news
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals reported its fiscal year 2023 results, highlighting the completion of enrollment in the Mino-Lok Phase 3 trial and plans for a LYMPHIR BLA resubmission in early 2024. The company also advanced two investigator-initiated trials for LYMPHIR and completed the Halo-Lido Phase 2b trial. Despite a net loss of $32.5 million, Citius remains optimistic about its pipeline and upcoming milestones.
Read more →CTXR▲ +6.9%on this news
Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Catheters Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals has completed enrollment in its pivotal Phase 3 trial for Mino-Lok, an antibiotic lock solution aimed at salvaging catheters in patients with catheter-related bloodstream infections. The trial enrolled 241 patients, surpassing the required 92 catheter failure events. Topline results are expected in Q2 2024, building on positive Phase 2 data. If successful, Mino-Lok would be the first FDA-approved treatment for this indication.
Read more →CTXR▲ +6.9%on this news
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update Mino-Lok Pivotal Phase 3 trial enrollment completed; topline data expected 2Q 2024 LYMPHIR BLA resubmission on tra
Citius Pharmaceuticals, Inc. announced its fiscal full year 2023 financial results and a business update, highlighting the completion of enrollment in its pivotal Phase 3 trial for Mino-Lok and the upcoming topline data expected in Q2 2024. The company also plans to resubmit its Biologics License Application for LYMPHIR in early 2024 after addressing FDA concerns. In addition, Citius completed its Phase 2b trial for Halo-Lido and is preparing for a spin-off of its oncology subsidiary. The financial report included a net loss of $32.5 million, with increases in operational expenses driven by pre-launch activities.
Read more →CTXRCitius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023 Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company developing and commercializing first-in-class...
Citius Pharmaceuticals will present at the Sidoti Micro-Cap Virtual Conference on November 15, 2023. CEO Leonard Mazur will discuss the company's advancements in critical care products, including Mino-Lok®, which is in a Phase 3 trial. The company is also preparing to resubmit its Biologics License Application for LYMPHIR in early 2024.
Read more →CTXRCitius Pharmaceuticals Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that preclinical research on LYMPHIR ("denileukin diftitox"...
Citius Pharmaceuticals announced positive preclinical results for LYMPHIR, showing enhanced anti-tumor activity when combined with an anti-PD-1 checkpoint inhibitor. The study indicates that this combination therapy improves overall survival in solid tumors compared to monotherapy. These findings have led to the initiation of two Phase 1 trials at prominent cancer research institutions.
Read more →CTXR▲ +17.4%on this news
Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc. Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company developing and commercializing...
Citius Pharmaceuticals has announced a merger with TenX Keane Acquisition to form Citius Oncology, Inc., retaining a 90% majority control. The transaction, valued at $675 million, is expected to close in the first half of 2024. Citius Oncology aims to commercialize LYMPHIR, a targeted therapy for cutaneous T-cell lymphoma, pending FDA approval.
Read more →CTXR▲ +17.4%on this news
Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc. Citius Pharmaceuticals, Inc. to receive $675 million in equi
Citius Pharmaceuticals has announced a definitive agreement to merge its wholly owned oncology subsidiary with TenX Keane Acquisition, creating a publicly listed entity named Citius Oncology, Inc. This merger, approved by both companies' Boards of Directors, is set to close in the first half of 2024. Citius Pharma will receive $675 million in equity from this transaction and retain a 90% majority ownership in the new company. Citius Oncology aims to develop novel oncology therapies, beginning with the FDA approval of its drug LYMPHIR for treating cutaneous T-cell lymphoma.
Read more →CTXRCitius Pharmaceuticals Reschedules Participation in Sidoti Small-Cap Virtual Investor Conference for November 2023 Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals has rescheduled its participation in the Sidoti Small-Cap Virtual Investor Conference to November 2023. This change is due to the funeral services for Howard Safir, a long-time board member. The company continues to focus on its late-stage product candidates, including Mino-Lok and LYMPHIR, which have received FDA designations.
Read more →CTXR▼ -6.5%on this newsshared move
Citius Pharmaceuticals Mourns the Loss of Board Member, Howard Safir Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) mourns the loss of longtime board member, Howard Safir, who passed away on...
Citius Pharmaceuticals announced the passing of Howard Safir, a longtime board member who served since 2014. His leadership and insights were instrumental in shaping the company's growth. The CEO expressed deep condolences to Safir's family and friends, highlighting his legacy of public service and contributions to the company.
Read more →CTXR▼ -10%on this newsshared move
NASDAQ: CTXR CLICK TO EDIT MASTER TITLE STYLE Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) Corporate Update SEPTEMBER 2023 NASDAQ: CTXR CLICK TO EDIT MASTER TITLE STYLE This presentation has been prepared by Citius Pharma
Citius Pharmaceuticals Inc. provided a corporate update highlighting its diversified pipeline and ongoing clinical trials. Key products include Mino-Lok, which is in Phase 3 trials and has shown strong efficacy against CLABSI. The company's financial health is robust, with $33.3 million in cash available through August 2024. However, the recent Complete Response Letter from the FDA requires them to enhance product testing before proceeding.
Read more →CTXRCitius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR™ Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) is pleased to announce the Company has received additional guidance from the...
Citius Pharmaceuticals has received regulatory guidance from the FDA for the planned resubmission of its Biologics License Application (BLA) for LYMPHIR, aimed at treating relapsed or refractory cutaneous T-cell lymphoma. The FDA's feedback supports Citius's plans to address previous requirements without needing additional clinical trials. The company anticipates completing the necessary activities by the end of 2023 and submitting the BLA in early 2024.
Read more →CTXRReceives Regulatory Guidance from the U.S.
Citius Pharmaceuticals has obtained regulatory guidance from the FDA concerning the upcoming resubmission of its Biologics License Application (BLA) for LYMPHIR, intended for treating relapsed or refractory cutaneous T-cell lymphoma (CTCL). With the FDA's agreement on the outlined requirements, Citius aims to complete the necessary activities for the resubmission by the end of this year and expects to file in early 2024. Importantly, the FDA has not requested additional clinical trials prior to this resubmission, signaling a constructive dialogue between the agency and the company.
Read more →CTXR▼ -5.3%on this newsshared move
Citius Pharmaceuticals to Participate in H.C. Wainwright and Sidoti Investor Conferences in September 2023 Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals will participate in two investor conferences in September 2023. CEO Leonard Mazur is set to present at the H.C. Wainwright Conference on September 11 and the Sidoti Small-Cap Virtual Conference on September 20. The company focuses on critical care products, including late-stage candidates like Mino-Lok and LYMPHIR.
Read more →CTXR▼ -6.7%on this news
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2023 Financial Results and Provides Business Update $33.3 million in cash and cash equivalents as of
Citius Pharmaceuticals, Inc. reported its fiscal third quarter 2023 financial results, showing a cash position of $33.3 million as of June 30, with a financial runway extended through August 2024 due to a $15 million capital raise. The company achieved critical milestones, including the required 92-event threshold for the Phase 3 Mino-Lok trial and positive topline results from the Phase 2b Halo-Lido trial. However, they faced regulatory challenges with the FDA's complete response letter for LYMPHIR, although no safety or efficacy concerns were raised. Citius plans to work closely with the FDA on a resubmission package to advance their product development efforts.
Read more →CTXRCitius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2023 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals reported its fiscal Q3 2023 results, highlighting significant progress in its clinical trials, including the completion of required events for the Phase 3 Mino-Lok trial. The company raised $15 million, extending its cash runway through August 2024. However, it faced a setback with the FDA's complete response letter for LYMPHIR, necessitating further testing before resubmission.
Read more →CTXR▲ +8.2%on this newsshared move
Citius Pharmaceuticals Reaches 92 Event Milestone in Mino-Lok® Phase 3 Trial Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and...
Citius Pharmaceuticals has announced the achievement of a significant milestone in its Phase 3 trial for Mino-Lok, an antibiotic lock solution aimed at treating catheter-related bloodstream infections. The company believes it has reached the required 92 events for trial completion, pending confirmation from an independent adjudication committee. The trial is designed to assess the efficacy and safety of Mino-Lok compared to standard care.
Read more →CTXR▲ +8.2%on this newsshared move
Citius Pharmaceuticals Reaches 92 Event Milestone in Mino-Lok Phase 3 Trial CRANFORD, N.J.
Citius Pharmaceuticals announced that it has achieved a key milestone in its Phase 3 trial for Mino-Lok, an antibiotic lock solution aimed at treating catheter-related bloodstream infections. The company believes it has reached all 92 required events, pending confirmation from an independent review committee. Mino-Lok is designed to salvage catheters, potentially reducing the need for catheter replacement and improving patient outcomes. The trial is being conducted in both the U.S. and India, with additional secondary outcome measures as part of the evaluation process.
Read more →CTXR▼ -11.6%on this news
Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that the U.S. Food and Drug Administration (FDA) has issued a ...
Citius Pharmaceuticals announced that the FDA issued a Complete Response Letter for its BLA of LYMPHIR (denileukin diftitox) for treating relapsed or refractory cutaneous T-cell lymphoma. The FDA did not raise concerns about the clinical efficacy or safety data but required enhanced product testing. Citius remains optimistic about the drug's potential and plans to provide additional data to the FDA.
Read more →CTXR▼ -11.6%on this news
Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Ce
Citius Pharmaceuticals, Inc. announced that the FDA issued a Complete Response Letter regarding its Biologics License Application for LYMPHIR, an engineered IL-2-diphtheria toxin fusion protein intended for treating relapsed or refractory cutaneous T-cell lymphoma. The FDA requested additional product testing and controls, but reassured there were no concerns about the safety and efficacy data. The company is committed to responding to these requirements and remains optimistic about LYMPHIR's potential impact on patient care.
Read more →CTXRNASDAQ: CTXR CLICK TO EDIT MASTER TITLE STYLE Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) Corporate Update JUNE 2023 NASDAQ: CTXR CLICK TO EDIT MASTER TITLE STYLE This presentation has been prepared by Citius Pharmaceuti
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) provided a corporate update detailing its diversified pipeline, including Mino-Lok, which may become a first-in-class treatment for managing catheter-related bloodstream infections. Positive results from early trials highlight Mino-Lok's potential efficacy and safety. The company's financial position is stable, with cash reserves extending into mid-2024. However, reliance on forward-looking statements presents risks regarding the actualization of projected milestones and regulatory approvals.
Read more →CTXRCitius Pharmaceuticals Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids CITI-002 provides a meaningful reduction in symptom severity when compared to individual
Citius Pharmaceuticals announced positive results from its Phase 2b study of Halo-Lido (CITI-002), which demonstrated a significant reduction in hemorrhoid symptoms compared to individual components. The study validated a Patient Reported Outcome tool and reported no significant adverse events, indicating a strong safety profile. Citius intends to move forward with an end of Phase 2 meeting with the FDA and is selecting a dose for a Phase 3 trial. These developments highlight the potential for CITI-002 to be a significant advancement in the treatment of hemorrhoids.
Read more →CTXR▲ +6.8%on this news
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2023 Financial Results and Provides Business Update $29.1 million in cash and cash equivalents as of
Citius Pharmaceuticals, Inc. released its fiscal second quarter 2023 financial results, reporting $29.1 million in cash reserves and a successful completion of its Halo-Lido Phase 2b trial. The company is optimistic about upcoming topline results and is progressing well in its Mino-Lok Phase 3 trial, with a key milestone expected by the end of the year. Citius has raised $15 million from investors to extend its operational runway through May 2024 and is advancing its I/ONTAK program in anticipation of a BLA decision. The company also acknowledges the need for additional capital to sustain operations beyond the upcoming fiscal periods.
Read more →CTXRCitius Pharmaceuticals Advances Mino-Lok Phase 3 Trial Achieving 85 of 92 Events to Date CRANFORD, N.J.
Citius Pharmaceuticals announced advancements in its Phase 3 trial for Mino-Lok, achieving 85 out of the required 92 events so far. The trial, which aims to evaluate the efficacy of this antibiotic lock solution for treating catheter-related bloodstream infections, has enrolled 190 patients at 35 clinical sites across the U.S. and India. The positive progression signals nearing completion, and Citius is optimistic about the treatment's potential approval by regulatory authorities.
Read more →CTXR▲ +14.5%on this news
Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids Topline Results anticipated by the end of Q2 2023 CRANFORD, N.J.
Citius Pharmaceuticals has successfully completed enrollment in its Phase 2b clinical study of Halo-Lido, a topical treatment for hemorrhoids, with 300 adults participating. The results are expected by the end of Q2 2023, which could pave the way for a Phase 3 study and potential FDA approval. This could mark the first prescription product indicated for the treatment of hemorrhoids, addressing an underserved market for this common condition.
Read more →CTXRCitius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2023 Financial Results and Provides Business Update $36.9 million in cash and cash equivalents as of
Citius Pharmaceuticals reported its fiscal first quarter 2023 financial results, revealing $36.9 million in cash and cash equivalents as of December 31, 2022, which is expected to support operations through February 2024. The company noted a recent increase in patient recruitment for its Mino-Lok Phase 3 trial, while the Halo-Lido Phase 2b trial is nearing completion. Additionally, Citius anticipates the FDA's decision on its I/ONTAK (E7777) BLA by late July. The company also announced the nomination of Dennis McGrath to its Board of Directors, strengthening its leadership team.
Read more →CTXRCitius Pharmaceuticals, Inc. Reports Fiscal Full Year 2022 Financial Results and Provides Business Update $41.7 million in cash and cash equivalents as of
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2022 Financial Results and Provides Business Update $41.7 million in cash and cash equivalents as of September 30, 2022; extends runway through December 2023 Mino-Lok Phase 3 trial closer to completion with 169 patients r
Read more →CTXR▲ +5.1%on this news
Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymp
Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma Drug User Fee Act (PDUFA) target action date is September 28
Read more →CTXRCitius Pharmaceuticals, Inc. Secures $3.6 million through New Jersey Economic Development Program Net operating losses converted into non-dilutive capital for ongoing R&D programs CRANFORD, N.J.
Citius Pharmaceuticals, Inc. Secures $3.6 million Economic Development Program Net operating losses converted into non-dilutive capital for ongoing R&D programs CRANFORD, N.J., November 21, 2022 -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a la
Read more →CTXRCitius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma CRA
Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma N.J., September 28, 2022 -- Citius Pharmaceuticals, Inc. ("Citius" o
Read more →CTXRCitius Pharmaceuticals Announces a Clinical Collaboration with the University of Pittsburgh to Evaluate T-reg Cell Depletion with I/ONTAK (E7777) in Combination with Pembrolizumab in Recurrent or Metastatic Solid Cancer
Citius Pharmaceuticals Announces a Clinical Collaboration with the University of Pittsburgh to Evaluate T-reg Cell Depletion with I/ONTAK (E7777) in Combination with Pembrolizumab in Recurrent or Metastatic Solid Cancer Tumors in a Phase 1 Investigator-Initiated Trial I/ONTAK
Read more →CTXR▲ +13.3%on this news
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2022 Financial Results and Provides Business Update $48.0 million in cash and cash equivalents as of
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2022 Financial Results and Provides Business Update $48.0 million in cash and cash equivalents as of June 30, 2022 to support ongoing programs through August 2023 International sites for Mino-Lok Phase 3 trial engaged
Read more →CTXRCitius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK (denileukin diftitox) for the Treatment of Cutaneous T-Cell Lymphoma Biologics License Application (BLA) submission planned for the second half
Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK (denileukin diftitox) for the Treatment of Cutaneous T-Cell Lymphoma Biologics License Application (BLA) submission planned for the second half of 2022 CRANFORD, N.J., July 12, 2022 -- Citius Pharmac
Read more →CTXRCitius Pharmaceuticals, Inc. Announces Intention to Spinoff Late-Stage Oncology Asset, I/ONTAK, into a New Standalone Publicly Traded Company IPO with distribution of shares to Citius shareholders planned for 2H 2022 Cit
Citius Pharmaceuticals, Inc. Announces Intention to Spinoff Late-Stage Oncology Asset, I/ONTAK, into a New Standalone Publicly Traded Company IPO with distribution of shares to Citius shareholders Citius would retain Mino-Lok and other pipeline assets and continue to trade on
Read more →CTXRCitius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2022 Financial Results and Provides Business Update Mino-Lok Phase 3 trial expanded to include sites outside the U.S.; trial enrollment expected to be completed
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2022 Financial Results and Provides Business Update Mino-Lok Phase 3 trial expanded to include sites outside the U.S.; trial enrollment expected to be completed by end of 2022 Topline results of Phase 3 trial in canc
Read more →CTXR▲ +6.9%on this news
Citius Pharmaceuticals to Accelerate Phase 3 Mino-Lok Trial by Expanding Trial Sites Internationally Additional sites to support trial completion by end of 2022 CRANFORD, N.J.
Citius Pharmaceuticals to Accelerate Phase 3 Mino-Lok Trial by Expanding Trial Sites Internationally Additional sites to support trial completion CRANFORD, N.J., May 6, 2022 - Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceuti
Read more →CTXRCitius Pharmaceuticals Enrolls First Patient in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids Primary endpoint is the reduction in hemorrhoidal symptoms CRANFORD, N.J.
Citius Pharmaceuticals Enrolls First Patient in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids Primary endpoint is the reduction in hemorrhoidal CRANFORD, N.J., April 26, 2022 -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR
Read more →CTXRCitius Pharmaceuticals Announces Key Management Realignment to Support Commercialization of Two Late-Stage Product Candidates Leonard Mazur named Chairman of the Board of Directors and CEO of Citius Citius co-founder, My
Citius Pharmaceuticals Announces Key Management Realignment to Support Commercialization of Two Late-Stage Product Candidates Leonard Mazur named Chairman of the Board of Directors and CEO of Citius Citius co-founder, Myron Holubiak to transition from President & CEO to Exec
Read more →CTXR▼ -7.1%on this news
Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK (E7777) for the Treatment of Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL) in Support of BLA Submissio
Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK (E7777) for the Treatment of Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL) in Support of BLA Submission CRANFORD, N.J., April 6, 2022 -- Citius Pharmaceutical
Read more →CTXR▲ +5.8%on this news
Citius Pharmaceuticals Announces FDA Acceptance of IND Application for its Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids Study expected to begin enrolling patients in the first half of 2022 He
Citius Pharmaceuticals Announces FDA Acceptance of IND Application for its Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids Study expected to begin enrolling patients in the first half of 2022 Hemorrhoids affect approximately 5% of the US population,
Read more →CTXRCitius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2022 Financial Results and Provides Business Update Strong balance sheet with $65.4 million in cash and cash equivalents as of
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2022 Financial Results and Provides Business Update Strong balance sheet with $65.4 million in cash and cash equivalents as of December 31, 2021 and no debt Topline results of Pivotal Phase 3 trial in cancer immunoth
Read more →CTXRCitius Pharmaceuticals, Inc. Reports Fiscal Full Year 2021 Financial Results and Provides Business Update $70.1 million in cash and cash equivalents as of
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2021 Financial Results and Provides Business Update $70.1 million in cash and cash equivalents as of September 30, 2021 to advance pipeline Completed treatment phase of Pivotal Phase 3 trial in cancer immunotherapy I/ONTA
Read more →CTXR▲ +7.9%on this news· ran to +22% by day 1
Citius Pharmaceuticals Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma Topline study results expected in the first half of 2022 Biologi
Citius Pharmaceuticals Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma Topline study results expected in the first Biologics License Application (BLA) filing anticipated in the second half of
Read more →CTXRCitius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications Citius expands late-stage pipe
Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications Citius expands late-stage pipeline with the acquisition of Dr. Reddy's exclusive licen
Read more →CTXRCitius Pharmaceuticals, Inc. Reports Third Fiscal Quarter 2021 Financial Results and Provides General Business Update $115.7 million in cash and cash equivalents as of
Pharmaceuticals, Inc. Reports Third Fiscal Quarter 2021 Financial Results and Provides General Business Update $115.7 million in cash and cash equivalents as of June 30, 2021 to develop pipeline and invest in long-term growth Mino-Lok Phase 3 superiority trial advancing foll
Read more →CTXRNASDAQ: CTXR CLICK TO EDIT MASTER TITLE STYLE Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) CORPORATE OVERVIEW JULY 2021 NASDAQ: CTXR CLICK TO EDIT MASTER TITLE STYLE This presentation has been prepared by Citius Pharmaceu
NASDAQ: CTXR CLICK TO EDIT MASTER TITLE STYLE Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) CORPORATE OVERVIEW JULY 2021 NASDAQ: CTXR CLICK TO EDIT MASTER TITLE STYLE This presentation has been prepared by Citius Pharmaceuticals, Inc . (the "Company") for informational purposes on
Read more →CTXRCitius Pharmaceuticals, Inc. Announces Positive Recommendation by Independent Data Monitoring Committee to Continue the Mino-Lok Phase 3 Trial as Planned - DMC interim safety and efficacy review of Mino-Lok
Citius Pharmaceuticals, Inc. Announces Positive Recommendation by Independent Data Monitoring Committee to Continue the Mino-Lok Phase 3 Trial as Planned - DMC interim safety and efficacy review of Mino-Lok Phase 3 Trial concluded with favorable recommendation to continue the
Read more →CTXRCitius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok Phase 3 Trial - Independent Data Monitoring Committee (DMC) to review Mino-Lok safety, superiority, and futility data at upcoming meeting sc
Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok Phase 3 Trial - Independent Data Monitoring Committee (DMC) to review Mino-Lok safety, superiority, and futility data at upcoming meeting scheduled for June 29, 2021- CRANFORD, N.J., June 8, 2021
Read more →CTXRCitius Pharmaceuticals to be Added to Russell 2000 Index CRANFORD, N.J.
Pharmaceuticals to be Added to Russell N.J., June 7, 2021 -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-inf
Read more →CTXRCitius Pharmaceuticals, Inc. Reports Second Fiscal Quarter 2021 Financial Results and Provides General Business Update Raised gross proceeds of $96.5 million from financing activities during the quarter providing financi
Citius Pharmaceuticals, Inc. Reports Second Fiscal Quarter 2021 Financial Results and Provides General Business Update Raised gross proceeds of $96.5 million from financing activities during the quarter providing financial runway into 2023 $103.7 million in cash and cash equi
Read more →CTXRCitius Pharmaceuticals Announces $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Cranford, NJ
Citius Pharmaceuticals Announces $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Cranford, NJ, February 17, 2021 - Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a specialty pharmaceutical company focused on developin
Read more →CTXRCitius Pharmaceuticals, Inc. Corporate Presentation Winter 2020 - 21 NASDAQ: CTXR 2 NASDAQ: CTXR This presentation has been prepared by Citius Pharmaceuticals, Inc. (the "Company") for informational purposes only and not
Citius Pharmaceuticals, Inc. Corporate Presentation Winter 2020 - 21 NASDAQ: CTXR 2 NASDAQ: CTXR This presentation has been prepared by Citius Pharmaceuticals, Inc. (the "Company") for informational purposes only and not for any other purpose. Nothing contained in this presentat
Read more →CTXRCitius Pharmaceuticals Announces $20.0 Million Private Placement Priced At-the-Market CRANFORD, N.J.
Pharmaceuticals Announces $20.0 Million Placement Priced At-the-Market N.J., January 25, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care dru
Read more →CTXRCitius Pharmaceuticals Receives FDA Response and Guidance to Pre-IND Consultation Submission for Mino-Wrap -- Mino-Wrap's novel approach to reducing post-mastectomy infections associated with the use of a tissue expander
Citius Pharmaceuticals Receives FDA Response and Guidance to Pre-IND Consultation Submission for Mino-Wrap -- Mino-Wrap's novel approach to reducing post-mastectomy infections associated with the use of a tissue expander is on track in its preclinical stage -- Some next steps
Read more →CTXRCitius Pharmaceuticals Subsidiary NoveCite Announces Data from a Study of Induced Mesenchymal Stem Cell (" i -MSC") Therapy in an in vivo Model of Acute Respiratory Distress Syndrome ("ARDS") --Interim results indicate i
Citius Pharmaceuticals Subsidiary NoveCite Announces Data from a Study of Induced Mesenchymal Stem Cell ("i-MSC") Therapy in an in vivo Respiratory Distress Syndrome ("ARDS") --Interim results indicate i-MSC therapy improves oxygenation and reduces lung injury --Efficiently
Read more →CTXRCitius Announces Results of Study that Mino-Lok Eradicates S. aureus Biofilm More Effectively and Expeditiously than Components Mino-Lok superior to EDTA and Ethanol in eradicating most worrisome pathogen Two strains of
Citius Announces Results of Study that Mino-Lok Eradicates S. aureus Biofilm More Effectively and Expeditiously than Components CRANFORD, NJ - November 30, 2020 - Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focuse
Read more →CTXR(908) 967-6677 x105 ascott@citiuspharma.com LETTER TO SHAREHOLDERS October 2020 Dear Fellow Shareholders, Citius Pharmaceuticals, Inc. ("Company") has made considerable progress in 2020 with recent developments designed
LETTER TO SHAREHOLDERS Dear Fellow Shareholders, Citius Pharmaceuticals, Inc. ("Company") has made considerable progress in 2020 with recent developments designed to contribute to increased value for our shareholders. Additionally, there are many upcoming milestones that coul
Read more →CTXRCitius Pharmaceuticals Signs an Exclusive Worldwide Licensing Agreement with Novellus Therapeutics for Unique i MSC-Therapy for Acute Inflammatory Respiratory Conditions including COVID-19 Related Acute Respiratory Distr
Pharmaceuticals Signs an Exclusive Worldwide Licensing Agreement with Novellus Therapeutics for Unique iMSC-Therapy for Acute Inflammatory Respiratory Conditions including COVID-19 Related Acute Respiratory Distress Syndrome (ARDS) NJ - October 7, 2020 - Citius Pharmaceuticals,
Read more →CTXRCitius Pharmaceuticals Reports Positive Results from Recent Data Monitoring Committee Meeting for Mino-Lok Phase 3 Trial DMC makes recommendation to continue trial with no modifications and requests an ad hoc meeting in
Pharmaceuticals Reports Positive Results from Recent Data Monitoring Committee Meeting for Mino-Lok Phase 3 Trial makes recommendation to continue trial with no modifications and requests an ad hoc meeting in near future N.J., Sept. 29, 2020 /PRNewswire/ -- Citius Pharmaceutica
Read more →CTXRCitius Pharmaceuticals Achieves Chemical Manufacturing and Control Milestones for Mino-Lok -Milestones include manufacturing of 3 registration lots for Mino-Lok CRANFORD, N.J.
Pharmaceuticals Achieves Chemical Manufacturing include manufacturing of 3 registration lots for Mino-Lok N.J., Sept. 22, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and
Read more →CTXRCitius Files Addendum to Mino-Lok Phase 3 Trial Record Keeping Protocol to Advance Trials with COVID-19 Compliance -Mino-Lok trial continues to progress despite challenges of conducting clinical trials in COVID-stressed
Addendum to Mino-Lok Phase 3 Trial Record Keeping Protocol with COVID-19 Compliance -Mino-Lok trial continues to progress despite challenges of conducting clinical trials in COVID-stressed sites -Interim efficacy review with Drug Monitoring Committee planned for end of this
Read more →CTXRCitius Pharmaceuticals Announces Improved Design and Expansion of Intellectual Property for Mino-Wrap Expansion of patents granted to The University of Texas System on behalf of M. D. Anderson Cancer Center CRANFORD, N.J
Pharmaceuticals Announces Improved Design and Expansion of Intellectual Property for Mino-Wrap of patents granted to The University of Texas System on behalf of M. D. Anderson Cancer Center N.J., Aug. 26, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Comp
Read more →CTXRCitius Pharmaceuticals, Inc. Corporate Presentation Fall 2020 NASDAQ: CTXR Disclaimer This presentation has been prepared by Citius Pharmaceuticals, Inc. (the "Company") for informational purposes only and not for any ot
Citius Pharmaceuticals, Inc. Corporate Presentation Fall 2020 NASDAQ: CTXR Disclaimer This presentation has been prepared by Citius Pharmaceuticals, Inc. (the "Company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or
Read more →CTXRCitius Pharmaceuticals Announces $6.0 Million Bought Deal Offering CRANFORD, N.J.
Citius Pharmaceuticals Announces $6.0 Million Bought Deal Offering CRANFORD, N.J., August 5, 2020 -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug produc
Read more →CTXRCitius Submits Mino-Wrap Briefing Package to FDA for Pre-IND Consult - Mino-Wrap being developed for the reduction of post-operative infections associated with breast reconstruction surgery - Mino-Wrap is the second majo
Mino-Wrap Briefing Package to FDA for Pre-IND Consult CRANFORD, N.J., August 4, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products announc
Read more →CTXRCitius Pharmaceuticals Brings on Myron S. Czuczman, M.D. as Chief Medical Officer (CMO) and Executive Vice President Recent executive at Celgene, Dr. Czuczman brings decades of experience in the strategic design and worl
Citius Pharmaceuticals Brings on Myron S. Czuczman, M.D. as Chief Medical Officer (CMO) and Executive Vice President CRANFORD, N.J., July 14, 2020 -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developi
Read more →CTXRCitius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute Respiratory Distress Syndrome (ARDS) in Patients with COVID-19 FDA provides ve
Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute Respiratory Distress Syndrome (ARDS) in Patients CRANFORD, N.J., June 26, 2020 - Citius Pharmaceuticals, Inc. ("Citius" or the "Company
Read more →CTXRCitius Receives Positive FDA Feedback on Its Submitted Plan to Study Catheter Compatibility for Mino-Lok Therapy Compatibility plan includes testing representative samples of all commercially available CVCs and PICCs Pla
Positive FDA Feedback on Its Submitted Plan to Study Catheter Compatibility for Mino-Lok Therapy CRANFORD, NJ - June 2, 2020 - Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing
Read more →CTXRCitius Announces Expanded Access Program for Investigational Phase 3 Mino-Lok The COVID-19 pandemic has highlighted the need to provide Mino-Lok on a compassionate case basis Many patients in hospitals receive medication
Citius Announces Expanded Access Program for Investigational Phase 3 Mino-Lok CRANFORD, N.J., May 26, 2020 -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care dr
Read more →CTXRCitius Announces $7.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Cranford, NJ
Citius Announces $7.5 Million Registered Priced At-the-Market under Nasdaq Rules Cranford, NJ, May 14, 2020 - Citius Pharmaceuticals Inc. (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced that
Read more →CTXR(908) 967-6677 x105 ascott@citiuspharma.com LETTER TO SHAREHOLDERS May 2020 Dear Fellow Shareholders, Our thoughts go out to all those affected by COVID-19. We especially want to express our gratitude and admiration to a
LETTER TO SHAREHOLDERS Dear Fellow Shareholders, Our thoughts go out to all those affected by COVID-19. We especially want to express our gratitude and admiration to all the front-line healthcare workers who are putting themselves at risk as they treat and comfort patients.
Read more →CTXRCitius Pharmaceuticals, Inc. Corporate Presentation Summer 2020 NASDAQ: CTXR Disclaimer This presentation has been prepared by Citius Pharmaceuticals, Inc. (the "Company") for informational purposes only and not for any
Citius Pharmaceuticals, Inc. Corporate Presentation Summer 2020 NASDAQ: CTXR Disclaimer This presentation has been prepared by Citius Pharmaceuticals, Inc. (the "Company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, o
Read more →CTXRCitius Announces Pre-IND Submission to FDA Under the Coronavirus Treatment Acceleration Program for a Novel Stem Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Company's goal to initiate clinical
Citius Announces Pre-IND Submission to FDA Under the Coronavirus Treatment Acceleration Program for a Novel Stem Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) CRANFORD, NJ - April 27, 2020 - Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR),
Read more →CTXRCitius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19 Novellus's patented mRNA-based cell-reprogramming technology creates
Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19 CRANFORD, NJ - April 1, 2020 - Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceut
Read more →CTXRCitius Pharmaceuticals Cites Independent Estimates of Total Available World Market for Mino-Lok According to DelveInsight, the market size of CRBSIs in the global market is expected to reach $1.84 billion in 2028, up fro
Citius Pharmaceuticals Cites Independent Estimates of Total Available World Market for Mino-Lok CRANFORD, N.J. - February 25, 2020 -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care
Read more →CTXRCitius Achieves 50% Patient Enrollment in Phase 3 Mino-Lok Pivotal Trial Next major milestone in Mino-Lok trial is the 75% interim analysis for superior efficacy and is expected in first half of 2020 CRANFORD, N.J.
Citius Achieves 50% Patient Enrollment in Phase 3 Mino-Lok Pivotal Trial Next major milestone in Mino-Lok trial is the 75% interim analysis for superior efficacy and is expected in first half of 2020 CRANFORD, N.J. February 4, 2020 -- Citius Pharmaceuticals, Inc. ("Citius" o
Read more →CTXRCitius Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements CRANFORD, N.J.
Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements N.J., February 3, 2020 - Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced
Read more →CTXRCitius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. Corporate Presentation Winter 2020 NASDAQ: CTXR 2 Disclaimer This presentation has been prepared by Citius Pharmaceuticals, Inc. (the "Company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is,
Read more →CTXRCitius Announces Positive Outcome of Interim Futility Analysis for its Phase 3 Mino-Lok Pivotal Trial Data Monitoring Committee recommends continuation of the trial with no changes CRANFORD, N.J.
Positive Outcome of Interim Futility Analysis for its Phase 3 Mino-Lok Pivotal Trial CRANFORD, N.J. - December 19, 2019 -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical
Read more →CTXRCitius Corporate Update November 2019 Dear Investors: Citius Pharmaceuticals, Inc. ("Company") has had a very productive and encouraging quarter. On
Citius Corporate Update Citius Pharmaceuticals, Inc. ("Company") has had a very productive and encouraging quarter. We are currently advancing three proprietary product candidates into large markets that are underserved by the current standards of care: Mino-Lok (FDA Phase I
Read more →CTXRCitius Reaches First Interim Analysis Milestone for Mino-Lok Pivotal Trial Study Reaches 40% Completion Triggering Data Cutoff for Futility Analysis CRANFORD, N.J.
Reaches First Interim Analysis Milestone for Mino-Lok Pivotal Trial N.J. - October 7, 2019 -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today reporte
Read more →CTXRCitius Announces Pricing of $7.0 Million Underwritten Offering Priced At-the-Market CRANFORD, NJ
Citius Announces Pricing of $7.0 Million Underwritten Offering Priced At-the-Market CRANFORD, NJ - September 25, 2019 - Citius Pharmaceuticals, Inc. ("Citius") ("Company") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug prod
Read more →CTXRCITIUS ANNOUNCES CHANGE TO PRIMARY ENDPOINT IN MINO-LOK PHASE 3 STUDY NEW ENDPOINT IMPROVES ABILITY TO CONDUCT STUDY MORE EXPEDITIOUSLY WITH SIGNIFICANTLY FEWER PATIENTS Clinical Trial Cost Savings Estimated to Approach
CITIUS ANNOUNCES CHANGE TO PRIMARY ENDPOINT IN MINO-LOK PHASE 3 STUDY NEW ENDPOINT IMPROVES ABILITY TO CONDUCT STUDY MORE EXPEDITIOUSLY WITH SIGNIFICANTLY FEWER PATIENTS Clinical Trial Cost Savings Estimated to Approach $10 million CRANFORD, N.J. - September 4, 2019 -- Citi
Read more →CTXRCitius Pharmaceuticals Presents Data on Mino-Lok Showing 98% Clinical Efficacy The Data Provides Proof of Salvaging Central Venous Catheters Colonized with Highly Virulent Pathogens in Patients with CLABSI/CRBSI CRANFORD
Pharmaceuticals Presents Data on Mino-Lok Showing 98% Clinical Efficacy The Data Provides Proof of Salvaging Central Venous Catheters Colonized with Highly Virulent Pathogens in Patients with CLABSI/CRBSI CRANFORD, N.J., April 30, 2019 - Citius Pharmaceuticals, Inc. ("Citius"
Read more →CTXRCitius Announces $5.3 Million Registered Direct Offering Priced At-the-Market CRANFORD, N.J.
Citius Announces $5.3 Million Registered Direct Offering Priced At-the-Market CRANFORD, N.J., April 1, 2019 -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced tha
Read more →CTXRDisclaimer This presentation has been prepared by Citius Pharmaceuticals, Inc.
2 Disclaimer This presentation has been prepared by Citius Pharmaceuticals, Inc. (the "Company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the
Read more →CTXRCITIUS LICENSES MINO-WRAP FROM MD ANDERSON CANCER CENTER - New technology designed to reduce infections after implantation of devices - First target is breast tissue expanders - Intended for minimizing serious complicati
LICENSES MINO-WRAP FROM MD ANDERSON CANCER CENTER N.J. - January 8, 2019 -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today reported that a definitive
Read more →CTXRCitius Announces Pricing of $10.0 Million Underwritten Offering Priced At-the-Market CRANFORD, NJ
Announces Pricing of $10.0 Million Underwritten Offering Priced At-the-Market NJ - August 9, 2018 - Citius Pharmaceuticals, Inc. (NASDAQ: CTXR, a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced the pricing of a
Read more →CTXRCITIUS PROVIDES CLINICAL UPDATE AND PROGRESS OF THE MINO-LOK PHASE 3 TRIAL PIVOTAL TRIAL ASSESSES THE EFFECTIVENESS AND SAFETY OF MINO-LOK IN THE TREATMENT OF INDIVIDUALS WITH CATHETER RELATED BLOOD STREAM INFECTIONS (CR
CITIUS PROVIDES CLINICAL UPDATE AND PROGRESS OF THE MINO-LOK PHASE 3 TRIAL PIVOTAL TRIAL ASSESSES THE EFFECTIVENESS AND SAFETY OF MINO-LOK IN THE TREATMENT OF INDIVIDUALS WITH CATHETER RELATED BLOOD STREAM INFECTIONS (CRBSIs) CRANFORD, N.J. - July 9, 2018 -- Citius Pharmaceut
Read more →CTXRCitius Announces $2.0 Million Registered Direct Offering Priced At-the-Market Cranford, NJ
Citius Announces $2.0 Million Registered Direct Offering Priced At-the-Market Cranford, NJ, March 29, 2017 - Citius Pharmaceuticals Inc. (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced that
Read more →CTXRCITIUS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN THE MINO-LOK PHASE 3 TRIAL PIVOTAL TRIAL TO ASSESS EFFECTIVENESS AND SAFETY OF MINO-LOK
CITIUS ANNOUNCES ENROLLMENT OF FIRST PATIENT IN THE MINO-LOK PHASE 3 TRIAL PIVOTAL TRIAL TO ASSESS EFFECTIVENESS AND SAFETY OF MINO-LOK IN THE TREATMENT OF INDIVIDUALS WITH CATHETER RELATED BLOOD STREAM INFECTIONS CRANFORD, N.J. - February 15, 2018 -- Citius Pharmaceuticals,
Read more →CTXRCitius Announces $6 Million Registered Direct Offering Priced At-the-Market Cranford, NJ
Citius Announces $6 Million Registered Direct Offering Priced At-the-Market Cranford, NJ, December 18, 2017 - Citius Pharmaceuticals Inc. (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced that
Read more →CTXRCitius Pharmaceuticals, Inc. Corporate Presentation Winter 2017 NASDAQ: CTXR 2 Disclaimer This presentation has been prepared by Citius Pharmaceuticals, Inc. (the "Company") for informational purposes only and not for an
Citius Pharmaceuticals, Inc. Corporate Presentation Winter 2017 NASDAQ: CTXR 2 Disclaimer This presentation has been prepared by Citius Pharmaceuticals, Inc. (the "Company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is,
Read more →CTXRInternational Study at MD Anderson Sister Institutions Supports Mino Lok Phase 2b Results: Poster Presented at ID Week Results showed a 95% efficacy in salvaging infected catheters for Mino-Lok CRANFORD, N.J.
Study at MD Anderson Sister Institutions Supports Mino Lok Phase 2b Results: Poster Presented at ID Week Results showed a 95% efficacy in salvaging infected catheters for Mino-Lok CRANFORD, N.J., November 7, 2017/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (CTXR),
Read more →CTXRCITIUS PHARMACEUTICALS, INC. RECEIVES "FAST TRACK" DESIGNATION BY FDA FOR MINO-LOK TM INVESTIGATIONAL TRIAL CRANFORD, N.J.
CITIUS PHARMACEUTICALS, INC. RECEIVES "FAST TRACK" DESIGNATION BY FDA FOR MINO-LOKTM INVESTIGATIONAL TRIAL CRANFORD, N.J. -- October 31, 2017 -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer
Read more →CTXRCitius Pharmaceuticals Shareholder Letter October 2017 Dear Citius Pharmaceuticals, Inc. Shareholder: I am pleased to report on some of the recent developments at Citius Pharmaceuticals (Nasdaq: CTXR), most notably, the
Citius Pharmaceuticals Shareholder Dear Citius Pharmaceuticals, Inc. Shareholder: I am pleased to report on some of the recent developments at Citius Pharmaceuticals (Nasdaq: CTXR), most notably, the successful listing of our shares on the Nasdaq. We believe that our presence
Read more →CTXRCITIUS PHARMACEUTICALS, INC. PRICES $6,800,000 PUBLIC OFFERING AND LISTING ON THE NASDAQ CAPITAL MARKET CRANFORD, NJ, AUGUST 3, 2017 - CITIUS PHARMACEUTICALS, INC. (NASDAQ: CTXR) , a specialty pharmaceutical company focu
CITIUS PHARMACEUTICALS, INC. PRICES $6,800,000 PUBLIC OFFERING AND LISTING ON THE NASDAQ CAPITAL MARKET CRANFORD, NJ, AUGUST 3, 2017 - CITIUS PHARMACEUTICALS, INC. (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug product
Read more →CTXRCitius Pharmaceuticals, Inc. Announces Closing of Public Offering CRANFORD, NJ, AUGUST 8, 2017 - CITIUS PHARMACEUTICALS, INC. (NASDAQ: CTXR) , a specialty pharmaceutical company focused on adjunctive cancer care and crit
Citius Pharmaceuticals, Inc. Announces Closing of Public Offering CRANFORD, NJ, AUGUST 8, 2017 - CITIUS PHARMACEUTICALS, INC. (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today the closing of its
Read more →CTXRCitius Pharma Announces Addition of South America to World License Worldwide License for Mino-Lok TM is Now Complete CRANFORD, N.J.
Citius Pharma Announces Addition of South America to Worldwide License for Mino-LokTM is Now Complete CRANFORD, N.J., March 23, 2017-- Citius Pharmaceuticals, Inc. ("Citius") (OTC BB: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care
Read more →CTXRCitius Pharmaceuticals Discontinues Suprenza To Focus on Core Assets
Citius Pharmaceuticals Discontinues Suprenza To Focus on Core Assets CRANFORD, N.J., July 1, 2016 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (OTC BB: CTXR), a specialty pharmaceutical company dedicated to acquiring, developing and commercializing adjunctive cancer care and cri
Read more →CTXRCitius Pharmaceuticals, Inc. Announces Appointment of Dr. Eugene Holuka to Its Board of Directors Cranford, NJ
Citius Pharmaceuticals, Inc. Announces Appointment of Dr. Eugene Holuka to Its Board of Directors Cranford, NJ-June 28, 2016- Citius Pharmaceuticals, Inc. (OTCQB: CTXR), (the "Company") announced today that it has appointed Dr. Eugene Holuka to the board of directors effective J
Read more →CTXRCitius Pharmaceuticals Completes Acquisition of Leonard-Meron Biosciences Acquisition provides Citius with a phase 3 ready critical care product Myron Holubiak appointed as President and Chief Executive Officer of Citius
Citius Pharmaceuticals Completes Acquisition of Leonard-Meron Biosciences Acquisition provides Citius with a phase 3 ready critical care product Myron Holubiak appointed as President and Chief Executive Officer of Citius LMB's senior executives join Citius and enhance mana
Read more →CTXRCitius Pharmaceuticals Signs Letter of Intent to Acquire Leonard Meron Biosciences Merger expands Citius' product portfolio to include a phase 3 ready critical care product Addition of accomplished pharma executives enha
Citius Pharmaceuticals Signs Letter of Intent to Acquire Leonard Meron Biosciences Merger expands Citius' product portfolio to include a phase 3 ready critical care product Addition of accomplished pharma executives enhances management presence Merger creates numerous oppo
Read more →CTXRCitius Pharmaceuticals Announces Results from Phase 2a Trial of Hydrocortisone and Lidocaine Combination Cream in Patients with Grade I and II Hemorrhoids Company advances commercialization of product into $1 billion ind
Citius Pharmaceuticals Announces Results from Phase 2a Trial of Hydrocortisone and Lidocaine Combination Cream in Patients with Grade I and II Hemorrhoids Company advances commercialization of product into $1 billion industry Combination product demonstrates positive directi
Read more →CTXRCitius Pharmaceuticals, Inc. Announces Appointment of Mr. Suren Dutia to Its Board of Directors Maynard, Massachusetts
Citius Pharmaceuticals, Inc. Announces Appointment of Mr. Suren Dutia to Its Board of Directors Maynard, Massachusetts-October 8, 2015- Citius Pharmaceuticals, Inc. (OTCQB: CTXR), (the "Company") announced today that it has appointed Mr. Suren Dutia to the board of directors eff
Read more →CTXRCitius Pharmaceuticals Announces Myron Holubiak, Former President of Roche Laboratories, Inc., USA, has Joined Its Board of Directors Maynard, Massachusetts
Citius Pharmaceuticals Announces Myron Holubiak, Former President of Roche Laboratories, Inc., USA, has Joined Its Board of Directors Maynard, Massachusetts-October 6, 2015-Citius Pharmaceuticals, Inc. (OTCQB: CTXR), (the "Company") announced today that it has appointed Mr. Myr
Read more →CTXRUNAUDITED PRO FORMA CONDENSED FINANCIAL STATEMENTS The following unaudited condensed pro forma balance sheet as of
UNAUDITED PRO FORMA CONDENSED FINANCIAL STATEMENTS The following unaudited condensed pro forma balance sheet as of June 30, 2014 was prepared as if the acquisition was effective as of such date. The unaudited condensed pro forma statements of operations for the year ended Septem
Read more →Competitive Position
How CTXR ranks across every disease it competes inCompetitive Position is a premium feature
See how CTXR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial